Based on this foundation, it was speculated that the poor prognosis of KRAS-mutated patients is due to the continuous activation of the Ras/Raf/MEK/ERK pathway caused by the KRAS gene mutation, which might lead to up-regulation of PD-L1 in tumor cells by abrogating autophagic degradation and further promoting the immune escape. This evidence concerns the gene MAP2K7 and neoplasm.